United Therapeutics (UTHR) Reports In-Line Q4 EPS, Beats on Revenues
Tweet
Share
E-mailGet Alerts UTHR Hot Sheet
Price: $494.63 -0.53%
EPS Growth %: -10.1%
Financial Fact:
Net income per basic common share (in dollars per share): 3.75
Today's EPS Names:
VIVO, OCCI, ALZN, More
EPS Growth %: -10.1%
Financial Fact:
Net income per basic common share (in dollars per share): 3.75
Today's EPS Names:
VIVO, OCCI, ALZN, More
Join SI Premium – FREE
United Therapeutics (NASDAQ: UTHR) reported Q4 EPS of $3.89, in-line with the analyst estimate of $3.89. Revenue for the quarter came in at $464.7 million versus the consensus estimate of $420.9 million.
For earnings history and earnings-related data on United Therapeutics (UTHR) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Westinghouse said to seek over $50 billion valuation in planned IPO
- Lumentum shares rise on analyst upgrades, AI demand outlook
- Vera Bradley (VRA) Tops Q2 EPS by 10c ; Offers Guidance
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
